DesignationRef.Download
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2015;2(4):269-39632615
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2016;4:262-37912601
ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2015;2(2):128-1355826
RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORKJ Prev Alz Dis 2016;3(2):114-1204943
THE ALZHEIMER’S PREVENTION CLINIC AT WEILL CORNELL MEDICAL COLLEGE / NEW YORK - PRESBYTERIAN HOSPITAL: RISK STRATIFICATION AND PERSONALIZED EARLY INTERVENTION J Prev Alz Dis 2015;2(4):254-2664940
VITAMIN D AND DEMENTIAJ Prev Alz Dis 2016;3(1):43-523977
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020J Prev Alz Dis 2020;7(S1):S55-S1193899
A PERSONALIZED 12-WEEK “BRAIN FITNESS PROGRAM” FOR IMPROVING COGNITIVE FUNCTION AND INCREASING THE VOLUME OF HIPPOCAMPUS IN ELDERLY WITH MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2016;3(3):133-1372538
REVERSIBLE AND SPECIES-SPECIFIC DEPIGMENTATION EFFECTS OF AZD3293, A BACE INHIBITOR FOR THE TREATMENT OF ALZHEIMER’S DISEASE, ARE RELATED TO BACE2 INHIBITION AND CONFINED TO EPIDERMIS AND HAIR J Prev Alz Dis 2016;3(4):202-2182356
BRIDGING THE GAP BETWEEN RESEARCH AND CLINICAL PRACTICE IN ASYMPTOMATIC ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(1):30-422251
CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIALJ Prev Alz Dis 2017;4(3):149-1562213
A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) J Prev Alz Dis 2015;2(4):227-2412174
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER’S DISEASE AND OTHER TAUOPATHIESJ Prev Alz Dis 2017;4(4):236-2412096
CLINICAL AND ECONOMIC CHARACTERISTICS OF MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: TRANSFORMING FUNCTIONAL SCORES INTO LEVELS OF DEPENDENCEJ Prev Alz Dis 2015;2(2):115-1202069
ETHICAL ISSUES IN THE DEVELOPMENT OF READINESS COHORTS IN ALZHEIMER’S DISEASE RESEARCHJ Prev Alz Dis 2017;4(2):125-1311964
THE RELATIONSHIP OF OMEGA 3 POLYUNSATURATED FATTY ACIDS IN RED BLOOD CELL MEMBRANES WITH COGNITIVE FUNCTION AND BRAIN STRUCTURE: A REVIEW FOCUSSED ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(1):78-841963
CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT” J Prev Alz Dis 2016;3(4):219-2281910
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(2):109-1151893
NEFLAMAPIMOD: CLINICAL PHASE 2B-READY ORAL SMALL MOLECULE INHIBITOR OF P38? TO REVERSE SYNAPTIC DYSFUNCTION IN EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(4):273-2781856
BRIDGING THE TRANSLATION GAP: FROM DEMENTIA RISK ASSESSMENT TO ADVICE ON RISK REDUCTIONJ Prev Alz Dis 2015;2(3):189-1981781
COMBINATION THERAPY OF ANTI-TAU AND ANTI-AMYLOID DRUGS FOR DISEASE MODIFICATION IN EARLY-STAGE ALZHEIMER’S DISEASE: SOCIO-ECONOMIC CONSIDERATIONS MODELED ON TREATMENTS FOR TUBERCULOSIS, HIV/AIDS AND BREAST CANCER J Prev Alz Dis 2016;3(3):164-1721757
POST HOC EVIDENCE FOR AN ADDITIVE EFFECT OF MEMANTINE AND DONEPEZIL: CONSISTENT FINDINGS FROM DOMINO-AD STUDY AND MEMANTINE CLINICAL TRIAL PROGRAMJ Prev Alz Dis 2015;2(3):165-1711671
FROM BRAIN DISEASE TO BRAIN HEALTH: PRIMARY PREVENTION OF ALZHEIMER’S DISEASE AND RELATED DISORDERS IN A HEALTH SYSTEM USING AN ELECTRONIC MEDICAL RECORD-BASED APPROACHJ Prev Alz Dis 2017;4(3):157-1641612
SHORT-TERM IMPACT OF A COMBINED NUTRACEUTICAL ON COGNITIVE FUNCTION, PERCEIVED STRESS AND DEPRESSION IN YOUNG ELDERLY WITH COGNITIVE IMPAIRMENT: A PILOT, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL J Prev Alz Dis 2017;4(1):12-151578
CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(3):138-1441454
MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER’S DISEASE: DESIGN AND BASELINE DATAJ Prev Alz Dis 2014;1(1):13-221452
THE ALZHEIMER’S PREVENTION INITIATIVE GENERATION PROGRAM: EVALUATING CNP520 EFFICACY IN THE PREVENTION OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(4):242-2461399
EVALUATION OF THE NEUROPROTECTIVE POTENTIAL OF N-ACETYLCYSTEINE FOR PREVENTION AND TREATMENT OF COGNITIVE AGING AND DEMENTIAJ Prev Alz Dis 2017;4(3):201-2061367
ANTI-TAU TRIALS FOR ALZHEIMER’S DISEASE: A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2019;6(3):157-1631164
THE ROSAS COHORT: A PROSPECTIVE, LONGITUDINAL STUDY OF BIOMARKERS FOR ALZHEIMER’S DISEASE. STRATEGY, METHODS AND INITIAL RESULTSJ Prev Alz Dis 2017;4(3):183-1931136
PIMAVANSERIN IN ALZHEIMER’S DISEASE PSYCHOSIS: EFFICACY IN PATIENTS WITH MORE PRONOUNCED PSYCHOTIC SYMPTOMSJ Prev Alz Dis 2019;6(1):27-331122
DEPENDENCE LEVELS AS INTERIM CLINICAL MILESTONES ALONG THE CONTINUUM OF ALZHEIMER’S DISEASE: 18-MONTH RESULTS FROM THE GERAS OBSERVATIONAL STUDYJ Prev Alz Dis 2017;4(2):72-801118
THE CASE FOR USING ACTIGRAPHY GENERATED SLEEP AND ACTIVITY ENDPOINTS IN ALZHEIMER’S DISEASE CLINICAL TRIALSJ Prev Alz Dis 2016;3(3):173-1761105
B-VITAMIN THERAPY FOR KIDNEY TRANSPLANT RECIPIENTS LOWERS HOMOCYSTEINE AND IMPROVES SELECTIVE COGNITIVE OUTCOMES IN THE RANDOMIZED FAVORIT ANCILLARY COGNITIVE TRIALJ Prev Alz Dis 2017;4(3):174-1821094
‘ALZHEIMER’S PROGRESSION SCORE’: DEVELOPMENT OF A BIOMARKER SUMMARY OUTCOME FOR AD PREVENTION TRIALSJ Prev Alz Dis 2016;3(4):229-2351048
FATTY ACIDS AND ALZHEIMER’S DISEASE: EVIDENCE ON COGNITION AND CORTICAL ?-AMYLOID FROM SECONDARY ANALYSES OF THE MULTIDOMAIN ALZHEIMER PREVENTIVE TRIALJ Prev Alz Dis 2018;5(3):168-1701037
VITAMIN E SUPPLEMENTATION REDUCES CELLULAR LOSS IN THE BRAIN OF A PREMATURE AGING MOUSE MODELJ Prev Alz Dis 2017;4(4):226-2351003
RATIONALE AND STRUCTURE FOR A NEW CENTER FOR STUDIES ON PREVENTION OF ALZHEIMER’S DISEASE (STOP-AD)J Prev Alz Dis 2016;3(4):236-242995
ALZHEIMER’S DISEASE DRUG DEVELOPMENT PIPELINE 2020J Prev Alz Dis 2020;7(2):66-67931
IDENTIFYING BETTER OUTCOME MEASURES TO IMPROVE TREATMENT OF AGITATION IN DEMENTIA: A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2018;5(2):98-102924
HEALTH LITERACY IN INDIVIDUALS AT RISK FOR ALZHEIMER’S DEMENTIA: A SYSTEMATIC REVIEWJ Prev Alz Dis 2020;7(1):47-55911
NANOROBOTS THE FUTURE OF NEUROLOGY: A PERSPECTIVE ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(2):155-156885
PLASMA BIOMARKERS OF AD EMERGING AS ESSENTIAL TOOLS FOR DRUG DEVELOPMENT: AN EU/US CTAD TASK FORCE REPORTJ Prev Alz Dis 2019;6(3):169-173857
WHAT HAVE WE LEARNED FROM EXPEDITION III AND EPOCH TRIALS? PERSPECTIVE OF THE CTAD TASK FORCEJ Prev Alz Dis 2018;5(3):171-170799
PIMAVANSERIN: POTENTIAL TREATMENT FOR DEMENTIA-RELATED PSYCHOSISJ Prev Alz Dis 2018;5(4):253-258789
PSYCHOMETRIC PROPERTIES OF THE CLINICAL DEMENTIA RATING – SUM OF BOXES AND OTHER COGNITIVE AND FUNCTIONAL OUTCOMES IN A PRODROMAL ALZHEIMER’S DISEASE POPULATIONJ Prev Alz Dis 2021;2(8):151-160758
THE FUTURE OF ANTI-AMYLOID TRIALSJ Prev Alz Dis 2020;3(7):146-151733
AN ACTION PLAN TO FACE THE CHALLENGE OF DEMENTIA: INTERNATIONAL STATEMENT ON DEMENTIA FROM IAP FOR HEALTHJ Prev Alz Dis 2018;5(3):207-212717
APPLICATION OF THE NIA-AA RESEARCH FRAMEWORK: TOWARDS A BIOLOGICAL DEFINITION OF ALZHEIMER’S DISEASE USING CEREBROSPINAL FLUID BIOMARKERS IN THE AIBL STUDYJ Prev Alz Dis 2019;6(4):248-255681
REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCEJ Prev Alz Dis 2016;3(2):68-74679
THE EUROPEAN PREVENTION OF ALZHEIMER’S DEMENTIA (EPAD) LONGITUDINAL COHORT STUDY: BASELINE DATA RELEASE V500.0J Prev Alz Dis 2020;7(1):8-13651
IMPLICATIONS FOR BACE1 INHIBITOR CLINICAL TRIALS: ADULT CONDITIONAL BACE1 KNOCKOUT MICE EXHIBIT AXONAL ORGANIZATION DEFECTS IN THE HIPPOCAMPUSJ Prev Alz Dis 2019;6(2):78-84631
MULTIDOMAIN INTERVENTIONS TO PREVENT COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, AND DEMENTIA: FROM FINGER TO WORLD-WIDE FINGERSJ Prev Alz Dis 2020;7(1):29-36609
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN PRIMARY CAREJ Prev Alz Dis 2020;3(7):165-170604
RATIONALE FOR EARLY DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (MCI) SUPPORTED BY EMERGING DIGITAL TECHNOLOGIESJ Prev Alz Dis 2020;3(7):158-164538
NON-AMYLOID APPROACHES TO DISEASE MODIFICATION FOR ALZHEIMER’S DISEASE: AN EU/US CTAD TASK FORCE REPORTJ Prev Alz Dis 2020;3(7):152-157536
INTEGRATED CARE FOR OLDER PEOPLE AND THE IMPLEMENTATION IN THE INSPIRE CARE COHORTJ Prev Alz Dis 2020;7(2):70-74520
POLYGENIC RISK SCORE ANALYSIS OF ALZHEIMER’S DISEASE IN CASES WITHOUT APOE4 OR APOE2 ALLELESJ Prev Alz Dis 2019;6(1):16-19504
REVISITING THE HALLMARKS OF AGING TO IDENTIFY MARKERS OF BIOLOGICAL AGEJ Prev Alz Dis 2020;7(1):56-64502
EARLY DETECTION OF MILD COGNITIVE IMPAIRMENT (MCI) IN AN AT-HOME SETTINGJ Prev Alz Dis 2020;3(7):171-178500
THE INTERRELATIONSHIP BETWEEN INSULIN-LIKE GROWTH FACTOR 1, APOLIPOPROTEIN E Ε4, LIFESTYLE FACTORS, AND THE AGING BODY AND BRAINJ Prev Alz Dis 2020;4(7):265-273499
A TURNING POINT IN ALZHEIMER’S RESEARCH: HARMONIZED RESEARCH STRATEGIES AND NOVEL INVESTMENTS IN PUBLIC HEALTH INFRASTRUCTURE ARE REENERGIZING THE FIELD, AND REKINDLING HOPE FOR THOSE AFFECTED BY ALZHEIMER’S AND RELATED DEMENTIASJ Prev Alz Dis 2019;6(4):214-216492
CAN DIGITAL TECHNOLOGY ADVANCE THE DEVELOPMENT OF TREATMENTS FOR ALZHEIMER’S DISEASE?J Prev Alz Dis 2019;6(4):217-220483
CORRELATION OF CSF- AND MRI-BIOMARKERS AND PROGRESSION OF COGNITIVE DECLINE IN AN OPEN LABEL MCI TRIALJ Prev Alz Dis 2018;5(3):202-206482
CORTICAL Β-AMYLOID IN OLDER ADULTS IS ASSOCIATED WITH MULTIDOMAIN INTERVENTIONS WITH AND WITHOUT OMEGA 3 POLYUNSATURATED FATTY ACID SUPPLEMENTATIONJ Prev Alz Dis 2020;7(2):128-134476
UTILIZATION OF OBSERVATIONAL DATA AS A PROXY COHORT FOR COMPARISON PURPOSES WITH OPEN-LABEL STUDY RESULTS: AN EXAMPLE FROM ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(2):90-99474
TARGETING LIFESTYLE BEHAVIOR TO IMPROVE BRAIN HEALTH: USER-EXPERIENCES OF AN ONLINE PROGRAM FOR INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINEJ Prev Alz Dis 2020;3(7):184-194470
IMPACT OF THE COVID-19 OUTBREAK ON THE CLINICAL AND RESEARCH ACTIVITIES OF MEMORY CLINICS: AN ALZHEIMER’S DISEASE CENTER FACING THE COVID-19 CRISISJ Prev Alz Dis 2020;3(7):197-198464
DIET AS A RISK FACTOR FOR COGNITIVE DECLINE IN AFRICAN AMERICANS AND CAUCASIANS WITH A PARENTAL HISTORY OF ALZHEIMER’S DISEASE: A CROSS- SECTIONAL PILOT STUDY DIETARY PATTERNSJ Prev Alz Dis 2019;6(1):50-55444
A MISSED OPPORTUNITY FOR DEMENTIA PREVENTION? CURRENT CHALLENGES FOR EARLY DETECTION AND MODERN-DAY SOLUTIONSJ Prev Alz Dis 2020;4(7):291-293443
ESTABLISHING CLINICAL RELEVANCE IN PRECLINICAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2015;2(2):85-87427
ALZHEIMER’S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIDIET TRIAL IN PRODROMAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(4):232-236419
SCREENING FOR MILD COGNITIVE IMPAIRMENT: THERE IS THE WILL BUT IS THERE A WAY?J Prev Alz Dis 2020;3(7):144-145418
COGNITIVE/CLINICAL ENDPOINTS FOR PRE-DEMENTIA AD TRIALSJ Prev Alz Dis 2015;2(2):82-84415
TREATABLE VASCULAR RISK AND COGNITIVE PERFORMANCE IN PERSONS AGED 35 YEARS OR OLDER: LONGITUDINAL STUDY OF SIX YEARSJ Prev Alz Dis 2019;6(1):42-49405
THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER’S DISEASE DRUG DEVELOPMENT PROGRAMSJ Prev Alz Dis 2020;4(7):288-290396
POSSIBLE ENDPOINTS IN A PRODROMAL ALZHEIMER’S DISEASE TRIALJ Prev Alz Dis 2015;2(2):88-90380
THE COMPUTERIZED COGNITIVE COMPOSITE (C3) IN A4, AN ALZHEIMER’S DISEASE SECONDARY PREVENTION TRIALJ Prev Alz Dis 2021;1(8):59-67346
SAFETY AND EFFICACY OF LEMBOREXANT IN PATIENTS WITH IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND ALZHEIMER’S DISEASE DEMENTIA: RESULTS FROM A PHASE 2 RANDOMIZED CLINICAL TRIALJ Prev Alz Dis 2021;1(8):7-18344
NEXT-GENERATION ALZHEIMER’S THERAPEUTICS: LEVERAGING DEEP BIOLOGYJ Prev Alz Dis 2020;3(7):138-139319
PREDICTING AMYLOID BURDEN TO ACCELERATE RECRUITMENT OF SECONDARY PREVENTION CLINICAL TRIALSJ Prev Alz Dis 2020;4(7):213-218312
LETTER TO THE EDITOR REFERRING TO AISEN, P.S. AND R. RAMAN, FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020J Prev Alz Dis 2020;4(7):299-300293
THE ALZHEIMER’S PREVENTION REGISTRY: A LARGE INTERNET-BASED PARTICIPANT RECRUITMENT REGISTRY TO ACCELERATE REFERRALS TO ALZHEIMER’S-FOCUSED STUDIESJ Prev Alz Dis 2020;4(7):242-250288
A FRAMEWORK FOR DEVELOPING PHARMACOTHERAPY FOR AGITATION IN ALZHEIMER’S DISEASE: RECOMMENDATIONS OF THE ISCTM* WORKING GROUPJ Prev Alz Dis 2020;4(7):274-282281
TOULOUSE ALZHEIMER’S CLINICAL RESEARCH CENTER RECOVERY AFTER THE COVID-19 CRISIS: TELEMEDICINE AN INNOVATIVE SOLUTION FOR CLINICAL RESEARCH DURING THE CORONAVIRUS PANDEMICJ Prev Alz Dis 2020;4(7):301-304265
EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER’S PREVENTION TRIALSJ Prev Alz Dis 2017;4(2):116-124259
THE ROLE OF FUTILITY ANALYSES IN AD CLINICAL TRIALSJ Prev Alz Dis 2020;7(1):7253
THE SARS-COV-2 PANDEMIC AND THE BRAVE NEW DIGITAL WORLD OF ENVIRONMENTAL ENRICHMENT TO PREVENT BRAIN AGING AND COGNITIVE DECLINEJ Prev Alz Dis 2020;4(7):294-298247
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) PROJECT: AN OVERVIEWJ Prev Alz Dis 2020;4(7):208-212223
NUTRITION-BASED APPROACHES IN CLINICAL TRIALS TARGETING COGNITIVE FUNCTION: HIGHLIGHTS OF THE CTAD 2020J Prev Alz Dis 2021;2(8):118-122218
ESTABLISHING A TRIAL READY COHORT TO ACCELERATE ALZHEIMER’S CLINICAL TRIAL ENROLLMENT AND TREATMENTSJ Prev Alz Dis 2020;4(7):202-203204
AUTHORS RESPONSE TO UMBRICHT D, LETTER TO THE EDITOR REFERRING FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020J Prev Alz Dis 2020;4(7):300203
THE TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD): EXPERIENCE FROM THE FIRST 3 YEARSJ Prev Alz Dis 2020;4(7):234-241202
APPLICATION OF DIGITAL COGNITIVE BIOMARKERS FOR ALZHEIMER’S DISEASE: IDENTIFYING COGNITIVE PROCESS CHANGES AND IMPENDING COGNITIVE DECLINEJ Prev Alz Dis 2021;2(8):123-126199
RECRUITMENT INTO THE ALZHEIMER PREVENTION TRIALS (APT) WEBSTUDY FOR A TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRCPAD)J Prev Alz Dis 2020;4(7):219-225197
THIRTY-SIX-MONTH AMYLOID POSITRON EMISSION TOMOGRAPHY RESULTS SHOW CONTINUED REDUCTION IN AMYLOID BURDEN WITH SUBCUTANEOUS GANTENERUMABJ Prev Alz Dis 2021;1(8):3-6193
TRC-PAD: ACCELERATING RECRUITMENT OF AD CLINICAL TRIALS THROUGH INNOVATIVE INFORMATION TECHNOLOGYJ Prev Alz Dis 2020;4(7):226-233184
EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT?J Prev Alz Dis 2019;6(3):150177
ACCELERATING PRECLINICAL ALZHEIMER’S CLINICAL TRIALS THROUGH A TRIAL-READY COHORT WITH DIVERSE REPRESENTATIONJ Prev Alz Dis 2020;4(7):204-205176
POLYGENIC RISK SCORING IS AN EFFECTIVE APPROACH TO PREDICT THOSE INDIVIDUALS MOST LIKELY TO DECLINE COGNITIVELY DUE TO ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;1(8):78-83156
THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER’S DISEASE (TRC-PAD) – A FUNDAMENTAL ALLY IN AD PREVENTION RESEARCHJ Prev Alz Dis 2020;4(7):206-207153
CLINICAL DEVELOPMENT OF ADUCANUMAB, AN ANTI-A? HUMAN MONOCLONAL ANTIBODY BEING INVESTIGATED FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(4):255-263149
Clinical Trials and Aging: 13th Conference Clinical Trials Alzheimer’s Disease, November 4-7, 2020J Prev Alz Dis 2020;7(S1):S2-S54130
DIGITAL SCREENING FOR COGNITIVE IMPAIRMENT – A PROOF OF CONCEPT STUDYJ Prev Alz Dis 2021;2(8):127-134129
LONGITUDINAL COURSE OF AGITATION AND AGGRESSION IN PATIENTS WITH ALZHEIMER’S DISEASE IN A COHORT STUDY: METHODS, BASELINE AND LONGITUDINAL RESULTS OF THE A3C STUDYJ Prev Alz Dis 2021;2(8):199-209125
AMYLOID AND APOE STATUS OF SCREENED SUBJECTS IN THE ELENBECESTAT MISSIONAD PHASE 3 PROGRAMJ Prev Alz Dis 2021;2(8):218-223120
DEVELOPING DISEASE-MODIFYING TREATMENTS IN ALZHEIMER’S DISEASE – A PERSPECTIVE FROM ROCHE AND GENENTECHJ Prev Alz Dis 2017;4(4):264-272118
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2017;4(4):282-42896
DEVELOPMENT REVIEW OF THE BACE1 INHIBITOR LANABECESTAT (AZD3293/LY3314814)J Prev Alz Dis 2017;4(4):247-25483
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2018;5(S1):S1-S19683
EDITORIAL: TAU BASED THERAPEUTICS: ALTERNATIVE APPROACHES IN THE WAR ON ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(3):151-15282
COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2019;6(3):164-16881
WHAT WE LEARN FROM THE CTAD 2018 (CLINICAL TRIALS ALZHEIMER’S DISEASE)J Prev Alz Dis 2018;5(4):214-21578
TREATMENT EFFECTS OF VORTIOXETINE ON COGNITIVE FUNCTIONS IN MILD ALZHEIMER’S DISEASE PATIENTS WITH DEPRESSIVE SYMPTOMS: A 12 MONTH, OPEN-LABEL, OBSERVATIONAL STUDYJ Prev Alz Dis 2019;6(3):192-19778
THE 2018 REVISED FDA GUIDANCE FOR EARLY ALZHEIMER’S DISEASE: ESTABLISHING THE MEANINGFULNESS OF TREATMENT EFFECTSJ Prev Alz Dis 2019;6(4):223-22776
CTAD: SYMPOSIA, ORAL COMMUNICATIONS, POSTERSJ Prev Alz Dis 2014;1(3):214-29674
EDITORIAL: IS NOW THE TIME FOR COMBINATION THERAPIES FOR ALZHEIMER DISEASE?J Prev Alz Dis 2019;6(3):153-15474
EDITORIAL: BLOOD TESTS FOR ALZHEIMER’S DISEASE AND RELATED DISORDERSJ Prev Alz Dis 2019;6(3):155-15670
BIOMARKER AND CLINICAL TRIAL DESIGN SUPPORT FOR DISEASE-MODIFYING THERAPIES: REPORT OF A SURVEY OF THE EU/US: ALZHEIMER’S DISEASE TASK FORCEJ Prev Alz Dis 2018;5(2):103-10964
DETECTING TREATMENT GROUP DIFFERENCES IN ALZHEIMER’S DISEASE CLINICAL TRIALS: A COMPARISON OF ALZHEIMER’S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE (ADAS-COG) AND THE CLINICAL DEMENTIA RATING - SUM OF BOXES (CDR-SB)J Prev Alz Dis 2018;5(1):15-2063
PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCEJ Prev Alz Dis 2015;2(3):184-18857
TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALSJ Prev Alz Dis 2018;5(1):31-3557
COMPARATIVE ANALYSIS OF DIFFERENT DEFINITIONS OF AMYLOID-Β POSITIVITY TO DETECT EARLY DOWNSTREAM PATHOPHYSIOLOGICAL ALTERATIONS IN PRECLINICAL ALZHEIMERJ Prev Alz Dis 2021;1(8):68-7757
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCEJ Prev Alz Dis 2019;6(3):180-18154
ITEM-LEVEL INVESTIGATION OF PARTICIPANT AND STUDY PARTNER REPORT ON THE COGNITIVE FUNCTION INDEX FROM THE A4 STUDY SCREENING DATA53
DELAYED-START ANALYSES IN THE PHASE 3 SOLANEZUMAB EXPEDITION3 STUDY IN MILD ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(1):8-1452
THE ROAD AHEAD TO CURE ALZHEIMER\'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONSJ Prev Alz Dis 2014;1(3):181-20249
ADVANCING ALZHEIMER’S DISEASE TREATMENT: LESSONS FROM CTAD 2018J Prev Alz Dis 2019;6(3):198-20348
A KETO-MEDIET APPROACH WITH COCONUT SUBSTITUTION AND EXERCISE MAY DELAY THE ONSET OF ALZHEIMER’S DISEASE AMONG MIDDLE-AGED J Prev Alz Dis 2017;4(1):51-5747
OVERSIMPLIFICATION OF DEMENTIA RISK REDUCTION MESSAGING IS A THREAT TO KNOWLEDGE TRANSLATION IN DEMENTIA PREVENTION RESEARCHJ Prev Alz Dis 2018;5(1):2-447
CONTINUING PROGRESS IN ALZHEIMER’S DISEASE TRIALS: CAUSE FOR OPTIMISMJ Prev Alz Dis 2017;4(4):211-21247
PLASMA BIOMARKER FOR ALZHEIMER’S DISEASE: ARE WE READY NOW FOR CLINICAL PRACTICE AND DRUG TRIALS?J Prev Alz Dis 2018;5(3):158-15947
COMMENTARY: DEVELOPMENT OF THE BLOOD-BASED ALZHEIMER’S DISEASE LIQUID BIOPSYJ Prev Alz Dis 2019;6(3):182-18447
ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE: THE ROAD AHEADJ Prev Alz Dis 2015;2(2):78-7946
MACHINE LEARNING ALGORITHM HELPS IDENTIFY NONDIAGNOSED PRODROMAL ALZHEIMER’S DISEASE PATIENTS IN THE GENERAL POPULATIONJ Prev Alz Dis 2019;6(3):185-19146
IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVEDJ Prev Alz Dis 2014;1(1):40-4545
ASSESSMENT OF CLINICAL MEANINGFULNESS OF ENDPOINTS IN THE GENERATION PROGRAM BY THE INSIGHTS TO MODEL ALZHEIMER’S PROGRESSION IN REAL LIFE (IMAP) STUDYJ Prev Alz Dis 2019;6(2):85-8944
E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS J Prev Alz Dis 2014;1(2):110-11643
LONGITUDINAL TRAJECTORIES OF CLINICAL DECLINE IN AMYLOID POSITIVE AND NEGATIVE POPULATIONSJ Prev Alz Dis 2016;3(2):92-10043
COMMENTARY: TREATING ALZHEIMER’S DISEASE : COMBINE OR FAIL ?J Prev Alz Dis 2019;6(3):174-17643
COMMENTARY: COMBINATION THERAPY FOR ALZHEIMER’S DISEASE – THE NEXT STEPJ Prev Alz Dis 2019;6(3):17943
GLOBAL ALZHEIMER’S PLATFORM TRIAL READY COHORTS FOR THE PREVENTION OF ALZHEIMER’S DEMENTIA J Prev Alz Dis 2016;3(4):185-18742
DRUG DEVELOPMENT IN AD: POINT OF VIEW FROM THE INDUSTRYJ Prev Alz Dis 2015;2(4):216-21841
UPDATE ON PREVENTION TRIALS IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(3):168-17539
ESTABLISHING COMPOSITE COGNITIVE ENDPOINTS FOR USE IN PRECLINICAL ALZHEIMER’S DISEASE TRIALSJ Prev Alz Dis 2015;2(1):2-339
RECRUITMENT OF AT-RISK PARTICIPANTS FOR CLINICAL TRIALS: A MAJOR PARADIGM SHIFT FOR ALZHEIMER’S DISEASE PREVENTIONJ Prev Alz Dis 2017;4(4):213-21439
RESULTS FROM A PHASE II STUDY TO ASSESS THE CLINICAL AND IMMUNOLOGICAL ACTIVITY OF AFFITOPE® AD02 IN PATIENTS WITH EARLY ALZHEIMER’S DISEASEJ Prev Alz Dis 2015;2(2):103-11438
THE ROAD AHEAD TO CURE AND PREVENT ALZHEIMER’S DISEASE: IMPLEMENTING PREVENTION INTO PRIMARY CAREJ Prev Alz Dis 2015;2(3):199-21138
PREVENTION: HOW THE PARADIGM IS SHIFTINGJ Prev Alz Dis 2014;1(1):51-5537
COMMENTARY: OPPORTUNITIES FOR COMBINATION TRIALSJ Prev Alz Dis 2019;6(3):177-17837
EDITORIAL: JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE (JPAD): BUILDING A “FLEET” AGAINST ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(1):2-336
PRIMARY PREVENTION OF DEMENTIA: THE FUTURE OF POPULATION-BASED MULTIDOMAIN LIFESTYLE INTERVENTIONSJ Prev Alz Dis 2018;5(1):5-736
A RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF THE EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITY, SAFETY AND AMYLOID IMAGING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(4):192-20134
THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS) FINDINGS FROM THE EXPEDITION3 TRIALJ Prev Alz Dis 2018;5(2):134-13634
EDITORIAL : DEMENTIA PREVENTION STRATEGIES – BEYOND THE RANDOMIZED CONTROLLED TRIAL?J Prev Alz Dis 2014;1(2):62-6433
INTERVENTIONS TO PREVENT COGNITIVE DECLINE AND DEMENTIA IN ADULTS WITHOUT COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEWJ Prev Alz Dis 2015;2(1):38-4533
NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA: OVERVIEW AND MEASUREMENT CHALLENGESJ Prev Alz Dis 2015;2(3):155-15633
PRECISION MEDICINE - THE GOLDEN GATE FOR DETECTION, TREATMENT AND PREVENTION OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(4):243-25933
BEYOND THE CONTROVERSY ON Aß BLOOD-BASED BIOMARKERSJ Prev Alz Dis 2015;2(1):51-5532
TRIAL DESIGN FOR THE EVALUATION OF NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: CONSIDERATIONS AND RECOMMENDATIONSJ Prev Alz Dis 2015;2(3):163-16432
METHODOLOGICAL ASPECTS OF THE PHASE II STUDY AFF006 EVALUATING AMYLOID-BETA -TARGETING VACCINE AFFITOPE® AD02 IN EARLY ALZHEIMER’S DISEASE – PROSPECTIVE USE OF NOVEL COMPOSITE SCALESJ Prev Alz Dis 2015;2(2):91-10232
FACEHBI: A PROSPECTIVE STUDY OF RISK FACTORS, BIOMARKERS AND COGNITION IN A COHORT OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. STUDY RATIONALE AND RESEARCH PROTOCOLSJ Prev Alz Dis 2017;4(2):100-10832
GETTING MORE CLINICALLY MEANINGFUL MEASURES OF FUNCTIONAL IMPAIRMENT FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2017;4(2):67-6832
HEALTHYBRAINS.ORG: FROM REGISTRY TO RANDOMIZATIONJ Prev Alz Dis 2016;3(3):123-12631
AT A CROSSROADS: A PERSPECTIVE ON DRUG DEVELOPMENT FOR ALZHEIMER’S DISEASE IN 2016 J Prev Alz Dis 2016;3(4):181-18431
PROSPECTIVE EVALUATION OF COGNITIVE HEALTH AND RELATED FACTORS IN ELDERLY AT RISK FOR DEVELOPING ALZHEIMER’S DEMENTIA: A LONGITUDINAL COHORT STUDYJ Prev Alz Dis 2019;6(4):256-26631
EDITORIAL : THE BRAINHEALTHREGISTRY.ORG: USING THE INTERNET FOR IDENTIFICATION, ASSESSMENT, SCREENING, RECRUITMENT, AND LONGITUDINAL MONITORING OF SUBJECTS FOR NEUROSCIENCE AND ALZHEIMER’S DISEASE STUJ Prev Alz Dis 2014;1(2):59-6130
CTAD 2016 abstract: EXPEDITION3: A PHASE 3 TRIAL OF SOLANEZUMAB IN MILD DEMENTIA DUE TO ALZHEIMER’S DISEASE30
EFFECTS OF OMEGA-3 FATTY ACIDS ON RESTING CEREBRAL PERFUSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT: A RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2018;5(1):26-3030
IS A LARGE-SCALE SCREENING FOR ALZHEIMER’S DISEASE POSSIBLE? YES, IN A FEW YEARSJ Prev Alz Dis 2019;6(4):221-22230
RANDOMIZED, PLACEBO CONTROLLED TRIAL OF NPT088, A PHAGE-DERIVED, AMYLOID-TARGETED TREATMENT FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(4):228-23130
EDITORIAL : MULTI-DOMAIN PREVENTION FOR A MULTI-FACTORIAL DISEASEJ Prev Alz Dis 2014;1(1):4-529
PRIMARY PREVENTION OF DEMENTIA: AN EPIDEMIOLOGICAL POINT OF VIEWJ Prev Alz Dis 2016;3(3):160-16329
PHYSICAL ACTIVITY AND ß-AMYLOID BRAIN LEVELS IN HUMANS: A SYSTEMATIC REVIEWJ Prev Alz Dis 2015;2(1):56-6328
COMMENT : A NEW ERA: DISEASE MODIFYING ALZHEIMER DISEASE PREVENTION TRIALS J Prev Alz Dis 2014;1(2):6828
DIETARY FACTORS AND COGNITIVE DECLINEJ Prev Alz Dis 2016;3(1):53-6428
THE FEASIBILITY OF AT-HOME IPAD COGNITIVE TESTING FOR USE IN CLINICAL TRIALSJ Prev Alz Dis 2016;3(1):8-1228
LESSONS TO BE LEARNED ABOUT CLINICAL TRIALS IN PRECLINICAL AD FROM ONGOING LONGITUDINAL STUDIESJ Prev Alz Dis 2015;2(4):214-21528
VANUTIDE CRIDIFICAR (ACC-001) AND QS-21 ADJUVANT IN INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE: AMYLOID IMAGING POSITRON EMISSION TOMOGRAPHY AND SAFETY RESULTS FROM A PHASE 2 STUDYJ Prev Alz Dis 2016;3(2):75-8428
PREVENTION OF ALZHEIMER’S DISEASE IN CHINESE POPULATIONS: STATUS, CHALLENGES AND DIRECTIONSJ Prev Alz Dis 2018;5(2):90-9428
MINIMIZING THE SAMPLE SIZES OF CLINICAL TRIALS ON PRECLINICAL AND EARLY SYMPTOMATIC STAGE OF ALZHEIMER DISEASEJ Prev Alz Dis 2018;5(2):110-11928
A LITERATURE REVIEW OF METHODOLOGIES USED IN RANDOMIZED CLINICAL TRIALS OF AGITATION IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(2):120-13328
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED J Prev Alz Dis 2014;1(1):8-1027
BLOOD-BRAIN BARRIER PERMEABILITY IN AGING AND ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(3):138-14027
AMYLOID AND TAU BIOMARKERS IN CSFJ Prev Alz Dis 2015;2(1):46-5027
INVESTIGATING FUNCTIONAL IMPAIRMENT IN PRECLINICAL ALZHEIMER’S DISEASEJ Prev Alz Dis 2015;2(1):4-627
MRI FOR PRE-DEMENTIA TRIALSJ Prev Alz Dis 2016;3(1):5-727
STUDIES OF AGITATION / AGGRESSION IN ALZHEIMER’S DISEASE – SCIENTIFIC AND OPERATIONAL CHALLENGESJ Prev Alz Dis 2015;2(3):157-15926
DEVELOPMENT OF AZELIRAGON, AN ORAL SMALL MOLECULE ANTAGONIST OF THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS, FOR THE POTENTIAL SLOWING OF LOSS OF COGNITION IN MILD ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(2):149-15426
CLINICAL APPLICATION OF APOE IN ALZHEIMER’S PREVENTION: A PRECISION MEDICINE APPROACHJ Prev Alz Dis 2018;5(4):245-25226
COMMENT: IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED?J Prev Alz Dis 2014;1(1):6-725
BASELINE SUBJECTIVE MEMORY COMPLAINTS ASSOCIATE WITH INCREASED RISK OF INCIDENT DEMENTIA: THE PREADVISE TRIALJ Prev Alz Dis 2015;2(1):11-1625
IMMUNOTHERAPY OF AD: ALUM DEMAIN?J Prev Alz Dis 2015;2(2):80-8125
REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER’S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCHJ Prev Alz Dis 2019;6(1):2-1525
LONGITUDINAL COMPARISON OF IN CLINIC AND AT HOME ADMINISTRATION OF THE COGSTATE BRIEF BATTERY AND DEMONSTRATED PRACTICE EFFECTS IN THE MAYO CLINIC STUDY OF AGINGJ Prev Alz Dis 2020;7(1):21-2825
NEW IPA CRITERIA FOR AGITATION IN COGNITIVE IMPAIRMENTJ Prev Alz Dis 2015;2(3):160-16224
COMPUTERIZED COGNITIVE TESTING FOR USE IN CLINICAL TRIALS: A COMPARISON OF THE NIH TOOLBOX AND COGSTATE C3 BATTERIESJ Prev Alz Dis 2017;4(1):3-1124
TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2018;5(3):160-16424
FACTORS ASSOCIATED WITH ALZHEIMER’S DISEASE: AN OVERVIEW OF REVIEWSJ Prev Alz Dis 2019;6(2):121-13424
IMPACT OF DIETARY FACTORS AND INFLAMMATION ON COGNITION AMONG OLDER ADULTSJ Prev Alz Dis 2015;2(4):220-22623
WEB-BASED SOFTWARE FOR REAL-TIME SIMULATION-ASSISTED TRIAL DESIGN IN ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(1):20-2323
TEA FOR ALZHEIMER PREVENTIONJ Prev Alz Dis 2015;2(2):136-14123
SELF-REPORTED MEMORY COMPLAINTS: A COMPARISON OF DEMENTED AND UNIMPAIRED OUTCOMESJ Prev Alz Dis 2016;3(1):13-1923
BARRIERS FOR PREVENTION AND PRODROMAL AD TRIALSJ Prev Alz Dis 2016;3(2):66-6723
THE VALUE OF PRE-SCREENING IN THE ALZHEIMER’S PREVENTION INITIATIVE (API) AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE TRIALJ Prev Alz Dis 2018;5(1):49-5423
ALZHEIMER’S PREVENTION EDUCATION: IF WE BUILD IT, WILL THEY COME? www.AlzU.orgJ Prev Alz Dis 2014;1(2):91-9822
COMMENT : ALZHEIMER’S DISEASE DRUG DEVELOPMENT: TRIAL-READY COHORTS SHOULD HELPJ Prev Alz Dis 2014;1(2):69-7022
ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA?J Prev Alz Dis 2014;1(3):141-14222
FOREWORD: AD DRUG DEVELOPMENT IS NOT BROKEN: CLINICAL TRIALS IN ALZHEIMER’S DISEASE 2014 CONFERENCE, PHILADELPHIAJ Prev Alz Dis 2014;1(3):212-21322
COGNITIVE REHABILITATION IN ALZHEIMER’S DISEASE – A CONCEPTUAL AND METHODOLOGICAL REVIEWJ Prev Alz Dis 2015;2(2):142-15222
A NOVEL STUDY PARADIGM FOR LONG-TERM PREVENTION TRIALS IN ALZHEIMER DISEASE: THE PLACEBO GROUP SIMULATION APPROACH (PGSA). APPLICATION TO MCI DATA FROM THE NACC DATABASEJ Prev Alz Dis 2014;1(2):99-10921
DEMENTIA PREVENTION: OPTIMIZING THE USE OF OBSERVATIONAL DATA FOR PERSONAL, CLINICAL, AND PUBLIC HEALTH DECISION-MAKING J Prev Alz Dis 2014;1(2):117-12321
ALZHEIMER’S ASSOCIATION: INITIATIVES & PUBLIC HEALTH PERSPECTIVEJ Prev Alz Dis 2016;3(4):178-18021
ADHERENCE TO THE MEDITERRANEAN DIET IS NOT RELATED TO BETA-AMYLOID DEPOSITION: DATA FROM THE WOMEN’S HEALTHY AGEING PROJECTJ Prev Alz Dis 2018;5(2):137-14121
COMMENT : E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS FOR STUDY J Prev Alz Dis 2014;1(2):66-6720
A PATIENT-CENTERED ANALYSIS OF ENROLLMENT AND RETENTION IN A RANDOMIZED BEHAVIORAL TRIAL OF TWO COGNITIVE REHABILITATION INTERVENTIONS FOR MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2014;1(3):143-15020
THE HARVARD AUTOMATED PHONE TASK: NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING TESTS FOR EARLY ALZHEIMER’S DISEASE J Prev Alz Dis 2015;2(4):242-25320
GINKGO BILOBA EXTRACT CONSUMPTION AND LONG-TERM OCCURRENCE OF DEATH AND DEMENTIAJ Prev Alz Dis 2017;4(1):16-2020
ALBUMIN, HEMOGLOBIN, AND THE TRAJECTORY OF COGNITIVE FUNCTION IN COMMUNITY-DWELLING OLDER JAPANESE: A 13-YEAR LONGITUDINAL STUDY J Prev Alz Dis 2017;4(2):93-9920
DEMENTIA PREVENTION BY DISEASE-MODIFICATION THROUGH NUTRITIONJ Prev Alz Dis 2017;4(3):138-13920
ARIZONA ALZHEIMER’S REGISTRY: STRATEGY AND OUTCOMES OF A STATEWIDE RESEARCH RECRUITMENT REGISTRY J Prev Alz Dis 2014;1(2):74-7919
COSTS AND RESOURCE USE ASSOCIATED WITH ALZHEIMER’S DISEASE IN ITALY: RESULTS FROM AN OBSERVATIONAL STUDYJ Prev Alz Dis 2018;5(1):55-6419
PLASMA A?42/40 RATIO DETECTS EARLY STAGES OF ALZHEIMER’S DISEASE AND CORRELATES WITH CSF AND NEUROIMAGING BIOMARKERS IN THE AB255 STUDYJ Prev Alz Dis 2019;6(1):34-4119
THINKING ABOUT COGNITIVE FRAILTYJ Prev Alz Dis 2015;2(1):7-1018
ASSESSMENT OF AGE-RELATED DIFFERENCES IN FUNCTIONAL CAPACITY USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT)J Prev Alz Dis 2015;2(2):121-12718
A NOVEL EIGENVECTOR-BASED METHOD TO DETECT MILD ALZHEIMER’S DISEASE USING EVENT-RELATED POTENTIALSJ Prev Alz Dis 2016;3(2):101-10418
PSYCHOMETRIC EVALUATION OF THE NEUROPSYCHOLOGICAL TEST BATTERY IN INDIVIDUALS WITH NORMAL COGNITION, MILD COGNITIVE IMPAIRMENT, OR MILD TO MODERATE ALZHEIMER’S DISEASE: RESULTS FROM A LONGITUDINAL STUDYJ Prev Alz Dis 2018;5(4):236-24418
AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENTJ Prev Alz Dis 2019;6(1):63-6918
AN OPEN-LABEL TRIAL OF YOKUKANSAN ON SLEEP DISTURBANCE IN ALZHEIMER’S DISEASE AND OTHER DEMENTIAJ Prev Alz Dis 2015;2(3):172-17717
NEUROPSYCHOLOGICAL PROFILE OF “COGNITIVE FRAILTY” SUBJECTS IN MAPT STUDYJ Prev Alz Dis 2016;3(3):151-15917
THE PARADOX OF RESEARCH ON DEMENTIA-ALZHEIMER’S DISEASEJ Prev Alz Dis 2016;3(4):189-19117
SWINGS AND ROUNDABOUTS IN CNS DRUG BIOMARKERSJ Prev Alz Dis 2017;4(3):134-13517
DESIGNING TRIALS OF DISEASE MODIFYING AGENTS FOR EARLY AND PRECLINICAL ALZHEIMER’S DISEASE INTERVENTION: WHAT EVIDENCE IS MEANINGFUL TO PATIENTS, PROVIDERS, AND PAYERS?J Prev Alz Dis 2019;6(1):20-2617
PTI-125 REDUCES BIOMARKERS OF ALZHEIMER’S DISEASE IN PATIENTSJ Prev Alz Dis 2020;4(7):256-26417
BRAIN DONATION BY PROXY: ARE THERE PREDICTORS IN NEURODEGENERATIVE DEMENTIA?J Prev Alz Dis 2014;1(3):151-15916
THREE CARDINAL LESSONS FROM ADAPT – 10 YEARS ONJ Prev Alz Dis 2014;1(3):176-18016
INTEGRATING INFORMATION FROM FDG - AND AMYLOID PET FOR DETECTING DIFFERENT TYPES OF DEMENTIA IN OLDER PERSONS. A CASE-SERIES STUDYJ Prev Alz Dis 2016;3(3):127-13216
REPORT FROM THE FIRST CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) ASIA-CHINA 2018 : BRINGING TOGETHER GLOBAL LEADERSJ Prev Alz Dis 2019;6(2):144-14716
DIETARY FAT INTAKE AND COGNITIVE FUNCTION AMONG OLDER POPULATIONS: A SYSTEMATIC REVIEW AND META-ANALYSISJ Prev Alz Dis 2019;6(3):204-21116
COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER’S DISEASE ASSESSMENT SCALE – COGNITIVE SUBSCALE: A VALIDATION STUDYJ Prev Alz Dis 2019;6(4):237-24116
COMMENT: HIGH ALZHEIMER’S DISEASE STUDY COMPLEXITY - LOW SUCCESS RATEJ Prev Alz Dis 2014;1(1):11-1215
COMMENT : CLINICAL TRIALS FOR ALZHEIMER’S DISEASE TURNED A CORNER IN 2013’ J Prev Alz Dis 2014;1(2):71-7315
AURAPTENE IN THE PEELS OF CITRUS KAWACHIENSIS (KAWACHIBANKAN) CONTRIBUTES TO THE PRESERVATION OF COGNITIVE FUNCTION: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN HEALTHY VOLUNTEERSJ Prev Alz Dis 2018;5(3):197-20115
DIABETES MELLITUS AND COGNITIVE DECLINE – PREVENTION SHOULD NOT BE DELAYED!J Prev Alz Dis 2018;5(2):95-9715
FEMALE SEX AND ALZHEIMER’S RISK: THE MENOPAUSE CONNECTIONJ Prev Alz Dis 2018;5(4):225-23015
MEDITERRANEAN DIET AND MAGNETIC RESONANCE IMAGING-ASSESSED BRAIN ATROPHY IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2014;1(1):23-3214
HIPPOCAMPAL ASTROCYTES AND ALZHEIMER’S DISEASE J Prev Alz Dis 2014;1(2):124-12814
COMMUNITY-BASED INTERVENTION FOR PREVENTION OF DEMENTIA IN JAPANJ Prev Alz Dis 2015;2(1):71-7614
ANTIOXIDANTS IN THE DIET AND COGNITIVE FUNCTION: WHICH ROLE FOR THE MEDITERRANEAN LIFE-STYLE?J Prev Alz Dis 2017;4(1):58-6414
EPIGALLOCATECHIN 3-GALLATE AS AN INHIBITOR OF TAU PHOSPHORYLATION AND AGGREGATION: A MOLECULAR AND STRUCTURAL INSIGHTJ Prev Alz Dis 2017;4(4):218-22514
WHO GUIDELINES ON COMMUNITY-LEVEL INTERVENTIONS TO MANAGE DECLINES IN INTRINSIC CAPACITY: THE ROAD TO PREVENTION COGNITIVE DECLINE IN OLDER AGE?J Prev Alz Dis 2018;5(3):165-16714
INCREASED FUNCTIONAL CONNECTIVITY AFTER LISTENING TO FAVORED MUSIC IN ADULTS WITH ALZHEIMER DEMENTIAJ Prev Alz Dis 2019;6(1):56-6214
FEASIBILITY OF USING A WEARABLE BIOSENSOR DEVICE IN PATIENTS AT RISK FOR ALZHEIMER’S DISEASE DEMENTIAJ Prev Alz Dis 2020;7(2):104-11114
HIGHER COGNITIVE PERFORMANCE IS PROSPECTIVELY ASSOCIATED WITH HEALTHY DIETARY CHOICES: THE MAINE SYRACUSE LONGITUDINAL STUDYJ Prev Alz Dis 2015;2(1):24-3213
JPAD IS MOVING FASTJ Prev Alz Dis 2016;3(1):3-413
DIABETES MITIGATES THE ROLE OF MEMORY COMPLAINT IN PREDICTING DEMENTIA RISK: RESULTS FROM THE PREVENTION OF ALZHEIMER’S DISEASE WITH VITAMIN E AND SELENIUM STUDYJ Prev Alz Dis 2017;4(3):143-14813
CLINICAL EFFECTS OF ORAL TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATIONJ Prev Alz Dis 2017;4(3):136-13713
CARE MANAGEMENT TO PROMOTE TREATMENT ADHERENCE IN PATIENTS WITH COGNITIVE IMPAIRMENT AND VASCULAR RISK FACTORS: A DEMONSTRATION PROJECTJ Prev Alz Dis 2018;5(1):36-4113
COGNITIVE FRAILTY AND INCIDENCE OF DEMENTIA IN OLDER PERSONSJ Prev Alz Dis 2018;5(1):42-4813
MEMORY BROUGHT TO MIND. FIVE-YEAR FOLLOW-UP OF CASE FINDING AND INTERVENTION OF DEMENTIA IN A SWEDISH PRIMARY HEALTH CARE DISTRICTJ Prev Alz Dis 2015;2(1):17-2312
IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENTJ Prev Alz Dis 2015;2(1):64-7012
THE EFFECT OF VASCULAR NEUROPATHOLOGY ON LATE-LIFE COGNITION: RESULTS FROM THE SMART PROJECTJ Prev Alz Dis 2016;3(2):85-9112
SHORT-TERM PRACTICE EFFECTS AND AMYLOID DEPOSITION: PROVIDING INFORMATION ABOVE AND BEYOND BASELINE COGNITIONJ Prev Alz Dis 2017;4(2):87-9212
PROSPECTS FOR EFFECTIVE TREATMENT OF THE DEMENTIA-ALZHEIMER SYNDROME: A RENEWED ODYSSEY IN SEARCH OF THE MAGIC ELIXIRJ Prev Alz Dis 2017;4(4):215-21712
IMPLEMENTING A MEMORY CLINIC MODEL TO FACILITATE RECRUITMENT INTO EARLY PHASE CLINICAL TRIALS FOR MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASEJ Prev Alz Dis 2019;6(2):135-13812
BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDREDJ Prev Alz Dis 2019;6(2):112-12012
DATA-DRIVEN PARTICIPANT RECRUITMENT: FINDINGS FROM THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE 3J Prev Alz Dis 2020;7(2):122-12712
EFFECTIVENESS OF THE OPEN SCREENING PROGRAMS IN RECRUITING SUBJECTS TO PRODROMAL AND MILD ALZHEIMER’S DISEASE CLINICAL TRIALSJ Prev Alz Dis 2020;4(7):251-25512
THE TIMECOURSE OF GLOBAL COGNITIVE GAINS FROM SUPERVISED COMPUTER-ASSISTED COGNITIVE TRAINING: A RANDOMISED, ACTIVE-CONTROLLED TRIAL IN ELDERLY WITH MULTIPLE DEMENTIA RISK FACTORSJ Prev Alz Dis 2014;1(1):33-3911
NEW FINDINGS WITH REANALYSIS OF THE DOMINO TRIAL ?J Prev Alz Dis 2015;2(3):21211
ASSESSING THE RELATIONSHIP BETWEEN VITAMIN D STATUS AND IMPAIRMENTS IN COGNITIVE AND PHYSICAL PERFORMANCE IN OLDER ADULTS USING A DUAL TASK PHYSICAL PERFORMANCE TEST J Prev Alz Dis 2017;4(1):29-3611
ASSOCIATIONS OF LONG-TERM TEA CONSUMPTION WITH DEPRESSIVE AND ANXIETY SYMPTOMS IN COMMUNITY-LIVING ELDERLY: FINDINGS FROM THE DIET AND HEALTHY AGING STUDYJ Prev Alz Dis 2018;5(1):21-2511
EFFECTS OF A SIX-MONTH MULTI-INGREDIENT NUTRITION SUPPLEMENT INTERVENTION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS, VITAMIN D, RESVERATROL, AND WHEY PROTEIN ON COGNITIVE FUNCTION IN OLDER ADULTS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIALJ Prev Alz Dis 2018;5(3):175-18311
ANALYSIS OF THE RELATIONSHIP OF COGNITIVE IMPAIRMENT AND FUNCTIONAL IMPAIRMENT IN MILD ALZHEIMER’S DISEASE IN EXPEDITION 3J Prev Alz Dis 2018;5(3):184-18711
ASSESSMENT OF INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT)J Prev Alz Dis 2018;5(4):216-22411
GEROSCIENCE AND THE ROLE OF AGING IN THE ETIOLOGY AND MANAGEMENT OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2020;7(1):2-311
A MACHINE LEARNING FRAMEWORK FOR ASSESSMENT OF COGNITIVE AND FUNCTIONAL IMPAIRMENTS IN ALZHEIMER’S DISEASE: DATA PREPROCESSING AND ANALYSISJ Prev Alz Dis 2020;7(2):87-9411
FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESSJ Prev Alz Dis 2020;3(7):195-19611
OVERTREATING ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;2(8):234-23611
CEREAL INTAKE INCREASES AND DAIRY PRODUCTS DECREASE RISK OF COGNITIVE DECLINE AMONG ELDERLY FEMALE JAPANESEJ Prev Alz Dis 2014;1(3):160-16710
THE RELATIONSHIP OF HEMOGLOBIN LEVELS, DELIRIUM AND COGNITIVE STATUS IN HOSPITALIZED GERIATRIC PATIENTS: RESULTS FROM THE CRIME STUDYJ Prev Alz Dis 2015;2(3):178-18310
STIMULUS-LOCKED LATERALIZED READINESS POTENTIAL AND PERFORMANCE: USEFUL MARKERS FOR DIFFERENTIATING BETWEEN AMNESTIC SUBTYPES OF MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2017;4(1):21-2810
SEX AND AGE DIFFERENCES IN THE ASSOCIATION OF BLOOD PRESSURE AND HYPERTENSION WITH COGNITIVE FUNCTION IN THE ELDERLY: THE RANCHO BERNARDO STUDYJ Prev Alz Dis 2017;4(3):165-17310
COMBINING GEOSPATIAL ANALYSIS WITH DEMENTIA RISK UTILISING GENERAL PRACTICE DATA: A SYSTEMATIC REVIEWJ Prev Alz Dis 2018;5(1):71-7710
DEMENTIA: CREATING A KNOWLEDGE-BASED HEALTHCARE PROFESSIONJ Prev Alz Dis 2018;5(1):85-8610
LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLYJ Prev Alz Dis 2018;5(1):8710
DETECTION OF RATER ERRORS ON COGNITIVE INSTRUMENTS IN A CLINICAL TRIAL SETTINGJ Prev Alz Dis 2018;5(3):188-19610
BIFIDOBACTERIUM BREVE A1 SUPPLEMENTATION IMPROVED COGNITIVE DECLINE IN OLDER ADULTS WITH MILD COGNITIVE IMPAIRMENT: AN OPEN-LABEL, SINGLE-ARM STUDYJ Prev Alz Dis 2019;6(1):70-7510
MEDITERRANEAN-DASH INTERVENTION FOR NEURODEGENERATIVE DELAY (MIND) DIET SLOWS COGNITIVE DECLINE AFTER STROKEJ Prev Alz Dis 2019;6(4):267-27310
COST-EFFECTIVENESS OF DEMENTIA PREVENTION INTERVENTIONSJ Prev Alz Dis 2021;2(8):210-21710
CURCUMIN MICELLES IMPROVE MITOCHONDRIAL FUNCTION IN A MOUSE MODEL OF ALZHEIMER’S DISEASE J Prev Alz Dis 2014;1(2):80-839
MODERATE, REGULAR ALCOHOL CONSUMPTION IS ASSOCIATED WITH HIGHER COGNITIVE FUNCTION IN OLDER COMMUNITY-DWELLING ADULTSJ Prev Alz Dis 2016;3(2):105-1139
COGNITIVE PERFORMANCE DOES NOT LIMIT PHYSICAL ACTIVITY PARTICIPATION IN THE LIFESTYLE INTERVENTIONS AND INDEPENDENCE FOR ELDERS PILOT STUDY (LIFE-P)J Prev Alz Dis 2017;4(1):44-509
EXPANDING THE TOOLKIT FOR STUDIES OF AGINGJ Prev Alz Dis 2017;4(2):69-709
INTER-SPECIES GLIA DIFFERENCES: IMPLICATIONS FOR SUCCESSFUL TRANSLATION OF TRANSGENIC RODENT ALZHEIMER’S DISEASE MODEL TREATMENT USING BEXAROTENEJ Prev Alz Dis 2014;1(1):46-508
EFFECT OF PUNICALAGIN AND RESVERATROL ON METHIONINE SULFOXIDE REDUCTASE: A POSSIBLE PROTECTIVE CONTRIBUTION AGAINST ALZHEIMER DISEASEJ Prev Alz Dis 2015;2(1):33-378
MODEST OVERWEIGHT AND HEALTHY DIETARY HABITS REDUCE RISK OF DEMENTIA: A NATIONWIDE SURVEY IN TAIWANJ Prev Alz Dis 2017;4(1):37-438
OBJECTIVE COGNITIVE IMPAIRMENT AND PROGRESSION TO DEMENTIA IN WOMEN: THE PROSPECTIVE EPIDEMIOLOGICAL RISK FACTOR STUDYJ Prev Alz Dis 2017;4(3):194-2008
ACTIVITIES OF DAILY LIVING MEASURED BY THE HARVARD AUTOMATED PHONE TASK TRACK WITH COGNITIVE DECLINE OVER TIME IN NON-DEMENTED ELDERLYJ Prev Alz Dis 2017;4(2):81-868
POTENTIAL UTILITY OF PRACTICE EFFECTS IN PREVENTIVE TRIALSJ Prev Alz Dis 2017;4(3):140-1428
STRONG RELATIONSHIP BETWEEN MALNUTRITION AND COGNITIVE FRAILTY IN THE SINGAPORE LONGITUDINAL AGEING STUDIES (SLAS-1 AND SLAS-2)J Prev Alz Dis 2018;5(2):142-1488
RESPONSES: LONG-TERM TEA CONSUMPTION AND DEPRESSIVE AND ANXIETY SYMPTOMS IN ELDERLYJ Prev Alz Dis 2018;5(1):878
CROSS-SECTIONAL CHARACTERIZATION OF ALBUMIN GLYCATION STATE IN CEREBROSPINAL FLUID AND PLASMA FROM ALZHEIMER’S DISEASE PATIENTSJ Prev Alz Dis 2019;6(2):139-1438
SHIFT IN HOSPITALIZATIONS FOR ALZHEIMER’S DISEASE TO RELATED DEMENTIAS IN FRANCE BETWEEN 2007 AND 2017J Prev Alz Dis 2019;6(2):108-1118
LINKING GEROSCIENCE AND INTEGRATED CARE TO REINFORCE PREVENTIONJ Prev Alz Dis 2020;7(2):68-698
NEUROPROTECTIVE EFFECTS OF A VARIETY OF POMEGRANATE JUICE EXTRACTS (PJE) AGAINST THE EXCITOTOXIN QUINOLINIC ACID IN HUMAN PRIMARY NEURONS J Prev Alz Dis 2014;1(2):84-907
GINKGETIN AMELIORATES NEUROPATHOLOGICAL CHANGES IN APP/PS1 TRANSGENICAL MICE MODELJ Prev Alz Dis 2016;3(1):24-297
EFFECTS OF THE VACCINE VANUTIDE CRIDIFICAR WITH QS-21 ADJUVANT ON IMMUNOGENICITYJ Prev Alz Dis 2016;3(4):1887
LETTER TO THE EDITOR: PREVENTING DEMENTIA THROUGH COMMUNITY INVOLVEMENT AND ALTRUISTIC BEHAVIORSJ Prev Alz Dis 2018;5(4):259-2607
GEOGRAPHIC CLUSTERS OF ALZHEIMER’S DISEASE MORTALITY RATES IN THE USA: 2008-2012J Prev Alz Dis 2018;5(4):231-2357
MRI CLINICAL RATINGS AND COGNITIVE FUNCTION IN A CROSS-SECTIONAL POPULATION STUDY OF DEMENTIA: THE CACHE COUNTY MEMORY STUDYJ Prev Alz Dis 2019;6(2):100-1077
FINANCIAL MANAGEMENT SKILLS IN AGING, MCI AND DEMENTIA: CROSS SECTIONAL RELATIONSHIP TO 18F-FLORBETAPIR PET CORTICAL Β-AMYLOID DEPOSITIONJ Prev Alz Dis 2019;6(4):274-2827
NEUROPSYCHOLOGICAL, PSYCHIATRIC, AND FUNCTIONAL CORRELATES OF CLINICAL TRIAL ENROLLMENTJ Prev Alz Dis 2019;6(4):242-2477
THE EU/US TASK FORCE’S FUTURE FOR ANTI-AMYLOID TRIALS: FAITES VOS JEUXJ Prev Alz Dis 2020;3(7):199-2007
NUTRITION TO PREVENT OR TREAT COGNITIVE IMPAIRMENT IN OLDER ADULTS: A GRADE RECOMMENDATIONJ Prev Alz Dis 2021;1(8):110-1166
PROSPECTIVE ASSOCIATIONS BETWEEN PLASMA AMYLOIDBETA 42/40 AND FRAILTY IN COMMUNITY-DWELLING OLDER ADULTSJ Prev Alz Dis 2021;1(8):41-476
SUGAR IN BEVERAGE AND THE RISK OF INCIDENT DEMENTIA, ALZHEIMER’S DISEASE AND STROKE: A PROSPECTIVE COHORT STUDYJ Prev Alz Dis 2021;2(8):188-1936
A WEB-BASED MULTIDOMAIN LIFESTYLE INTERVENTION FOR OLDER ADULTS: THE EMIND RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2021;2(8):142-1506
EFFECTS OF COMPUTERIZED COGNITIVE TRAINING ON GAIT SPEED IN COMMUNITY DWELLING OLDER ADULTS, A PILOT STUDYJ Prev Alz Dis 2016;3(3):145-1505
SELF-ADMINISTERED COGNITIVE TESTING BY OLDER ADULTS AT-RISK FOR COGNITIVE DECLINEJ Prev Alz Dis 2020;4(7):283-2875
EFFECTS OF A GROUP-BASED 8-WEEK MULTICOMPONENT COGNITIVE TRAINING ON COGNITION, MOOD AND ACTIVITIES OF DAILY LIVING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP OF A RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2020;7(2):112-1214
DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER’S DISEASE SPECTRUMJ Prev Alz Dis 2020;3(7):179-1834
IS RELUCTANCE TO SHARE ALZHEIMER’S DISEASE BIOMARKER STATUS WITH A STUDY PARTNER A BARRIER TO PRECLINICAL TRIAL RECRUITMENT?J Prev Alz Dis 2021;1(8):52-584
NEUROPROTECTIVE EFFECTS OF GUARANA (PAULLINIA CUPANA MART.) AGAINST VINCRISTINE IN VITRO EXPOSUREJ Prev Alz Dis 2018;5(1):65-703
EFFECTS OF RICE WINE LEES ON COGNITIVE FUNCTION IN COMMUNITY-DWELLING PHYSICALLY ACTIVE OLDER ADULTS: A PILOT RANDOMIZED CONTROLLED TRIALJ Prev Alz Dis 2020;7(2):95-1033
SEARCHING FOR THE HOLY GRAIL WILL NEED BIOMARKERSJ Prev Alz Dis 2020;7(1):4-63
THE PATIENT IN YOUR ALZHEIMER’S DISEASE STUDY MAY BE IN ANOTHER: DUPLICATION AND DECEPTION IN CLINICAL TRIALS OF ALZHEIMER’S DISEASEJ Prev Alz Dis 2020;7(1):43-463
EXPLORING FACTORS THAT CONTRIBUTE TO JOINING AND REGULARLY PRACTICING IN COGNITIVE TRAINING AMONG HEALTHY OLDER ADULTS: A ONE-YEAR FOLLOW-UP QUALITATIVE STUDYJ Prev Alz Dis 2020;7(2):75-813
AN INDUSTRY PERSPECTIVE: FUTURE OF ANTI-AMYLOID TRIALSJ Prev Alz Dis 2020;3(7):142-1433
A IS FOR AMYLOIDJ Prev Alz Dis 2020;3(7):140-1413
EDITORIAL : ALZHEIMER’S DISEASE PREVENTION: REALITY OR UTOPIA?2
EFFECTS ON COGNITION OF BERRY, POMEGRANATE, GRAPE AND BIOPHENOLS: A GENERAL REVIEW2
MENTAL COMPONENT SCORE (MCS) FROM HEALTH-RELATED QUALITY OF LIFE PREDICTS INCIDENCE OF DEMENTIA IN U.S. MALESJ Prev Alz Dis 2021;2(8):169-1742
A SYSTEMATIC REVIEW ON THE FEASIBILITY OF SALIVARY BIOMARKERS FOR ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;1(8):84-912
EXECUTIVE FUNCTION PREDICTS THE VALIDITY OF SUBJECTIVE MEMORY COMPLAINTS IN OLDER ADULTS BEYOND DEMOGRAPHIC, EMOTIONAL, AND CLINICAL FACTORSJ Prev Alz Dis 2021;2(8):161-1682
DOES TEA DRINKING PROMOTE HEALTH OF OLDER ADULTS: EVIDENCE FROM THE CHINA HEALTH AND NUTRITION SURVEYJ Prev Alz Dis 2021;2(8):194-1982
ELEVATED BLOOD HOMOCYSTEINE AND RISK OF ALZHEIMER’S DEMENTIA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS BASED ON PROSPECTIVE STUDIES2
ASSOCIATIONS OF LATER-LIFE EDUCATION, THE BDNF VAL66MET POLYMORPHISM AND COGNITIVE CHANGE IN OLDER ADULTSJ Prev Alz Dis 2020;7(1):37-421
ASSOCIATION OF VITAMIN D LEVELS WITH INCIDENT ALLCAUSE DEMENTIA IN LONGITUDINAL OBSERVATIONAL STUDIES: A SYSTEMATIC REVIEW AND META-ANALYSISJ Prev Alz Dis 2020;7(1):14-201
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA1
Clinical Trials and Aging: 12th Conference Clinical Trials on Alzheimer’s Disease, October 4-7, 2019, San Diego, USA1
KNOWLEDGE, ATTITUDE AND PREVENTIVE PRACTICE ON DEMENTIA CARE AMONG PRIMARY HEALTH PROFESSIONALS IN MACAOJ Prev Alz Dis 2020;7(2):83-861
THE EFFECT OF BASELINE PERFORMANCE AND AGE ON COGNITIVE TRAINING IMPROVEMENTS IN OLDER ADULTS: A QUALITATIVE REVIEWJ Prev Alz Dis 2021;1(8):100-1091
PHYSICAL FITNESS AND APOLIPOPROTEIN E GENOTYPE INFLUENCE CORTICAL NETWORKING AND INTELLIGENCE IN ADOLESCENTSJ Prev Alz Dis 2021;1(8):92-991
MOLECULAR SUBTYPING OF MILD COGNITIVE IMPAIRMENT BASED ON GENETIC POLYMORPHISM AND GENE EXPRESSIONJ Prev Alz Dis 2021;2(8):224-2331
CHINESE VERSION OF THE BAYLOR PROFOUND MENTAL STATUS EXAMINATION: A BRIEF STAGING MEASURE FOR PATIENTS WITH SEVERE ALZHEIMER’S DISEASEJ Prev Alz Dis 2021;2(8):175-1801
A NOVEL COMPUTERIZED COGNITIVE STRESS TEST TO DETECT MILD COGNITIVE IMPAIRMENTJ Prev Alz Dis 2021;2(8):135-1411